A multiple genome analysis of Mycobacterium tuberculosis reveals specific novel genes and mutations associated with pyrazinamide resistance
Name:
12864_2017_4146_MOESM1_ESM.docx
Size:
26.33Kb
Format:
Microsoft Word 2007
Description:
Supplemental files
Name:
12864_2017_4146_MOESM2_ESM.docx
Size:
1.240Mb
Format:
Microsoft Word 2007
Description:
Supplemental files
Type
ArticleAuthors
Sheen, PatriciaRequena, David
Gushiken, Eduardo
Gilman, Robert H.
Antiparra, Ricardo
Lucero, Bryan
Lizárraga, Pilar
Cieza, Basilio
Roncal, Elisa
Grandjean, Louis
Pain, Arnab
McNerney, Ruth
Clark, Taane G.
Moore, David J.
Zimic, Mirko
Date
2017-10-11Permanent link to this record
http://hdl.handle.net/10754/625883Metadata
Show full item recordAbstract
Tuberculosis (TB) is a major global health problem and drug resistance compromises the efforts to control this disease. Pyrazinamide (PZA) is an important drug used in both first and second line treatment regimes. However, its complete mechanism of action and resistance remains unclear.We genotyped and sequenced the complete genomes of 68 M. tuberculosis strains isolated from unrelated TB patients in Peru. No clustering pattern of the strains was verified based on spoligotyping. We analyzed the association between PZA resistance with non-synonymous mutations and specific genes. We found mutations in pncA and novel genes significantly associated with PZA resistance in strains without pncA mutations. These included genes related to transportation of metal ions, pH regulation and immune system evasion.These results suggest potential alternate mechanisms of PZA resistance that have not been found in other populations, supporting that the antibacterial activity of PZA may hit multiple targets.Citation
Sheen P, Requena D, Gushiken E, Gilman RH, Antiparra R, et al. (2017) A multiple genome analysis of Mycobacterium tuberculosis reveals specific novel genes and mutations associated with pyrazinamide resistance. BMC Genomics 18. Available: http://dx.doi.org/10.1186/s12864-017-4146-z.Sponsors
Some of this research and some members of the research team were funded by the Wellcome Trust (award 099805/Z/12/Z); the charity IFHAD: Innovation For Health And Development; DFID-CSCF; the Joint Global Health Trials consortium (MRC, DFID & Wellcome Trust); the Imperial College Biomedical Research Centre; and the National Institute of Allergy and Infectious Diseases, National Institutes of Health US, under the terms of Award 1R01TW008669-01. This study was also partially funded by Lóreal UNESCO, TWAS and Grand Challenge Canada. PS is a Wellcome Trust fellow. TGC receives funding from the MRC UK (MR/K000551/1, MR/M01360X/1, MR/N010469/1, MC_PC_15103). AP is supported by faculty baseline research fund from KAUST. MZ is a Bill and Melinda Gates Foundation grantee.Publisher
Springer NatureJournal
BMC GenomicsISSN
1471-2164PubMed ID
29020922Scopus Count
Except where otherwise noted, this item's license is described as This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.